Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
Kibum KimGwendolyn A McMillinPhilip S BernardSrinivas TantravahiBrandon S WalkerRobert L SchmidtPublished in: PloS one (2019)
Although the impact of TDM is modest, the cost-effectiveness over a lifetime horizon (societal perspective, ($30,450/QALY) falls within the acceptable range (< $100k/QALY).
Keyphrases